Cardiovascular regenerative medicine integrates research (both basic and applied) and patient care for regenerative medicine. We explore strategies to enhance efficacy, including potent cell types, cell less cell therapy approaches (e.g. miRNA, exosomes treatment), the smart use of biomaterials, and novel delivery strategies using state-of-the-art image fusion.
The translational axis drives our work. To this end, we utilize the abundant experience of the UU animal facility with a strong collaboration between the Hubrecht lab and the TU/e (Technical University, Eindhoven, NL). This creates an effective cross-pollination between the strategic programs of the UMC Utrecht namely Circulatory Health and Regenerative Medicine.
Our research is translational in nature, covering the range from basic research to clinical trials. Our studies include many areas from novel treatments for kidney damage using stem cells, to developing smart biomaterials that stimulate the bodies regeneration of defective heart valves, and the use of innovative imaging techniques in chorus with advanced echocardiography and histology/ bio banking of bone marrow, skin, artery and veins with the ultimate aim of restoring areas around the border of damaged sites, to name a few. In preclinical trials potency of cell therapy (e.g. cardiomyocyte progenitor cells, induced pluripotent stem cells) and other regenerative approaches are tested. We encouraged our research teams to participate in multicenter clinical trials (PRECISE, HEBE, LUMCU-HF), and initiate such trials as PI (e.g. JUVENTAS, AMICI, RIPASSA).
The stakes are high, as are expectations, yet our discipline takes tremendous time, effort, invention and patience to advance with expected high quality research. While the going can be slow at times, each movement brings us a step closer to the discoveries of new frontiers in medicine.
Our research focuses on:
G.J. de Borst, L.W. van Laake, J.P.G. Sluijter, M.C. Verhaar.